Germany's MediClin Q1 revenue rises 5.7%, helped by post-acute segment strength

MEDICLIN AG

04/05/2026 12:17

Overview

Germany healthcare provider's Q1 revenue rose 5.7% yr/yr to EUR 186.9 mln

Group operating result increased to EUR 9.3 mln from EUR 5.2 mln

Company cites stable occupancy and cost management for improved results

Outlook

MediClin expects 2026 revenue growth of 3.5% to 6.5%

Company maintains 2026 EBIT forecast of EUR 57.0 mln to EUR 72.0 mln

MediClin says reclassification does not affect full-year forecasts

Result Drivers

STABLE OCCUPANCY - MediClin said a stable occupancy rate supported financial performance, per CFO Tino Fritz

COST MANAGEMENT - Company cited successful cost management as a key factor in improved results, according to CFO Tino Fritz

POST-ACUTE SEGMENT - Operating result in the Post-acute segment rose by EUR 4.8 mln, driven by higher revenue and lower material costs

Company press release: ID:nEQ4J9L0ba

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
EUR 186.90 mln
Q1 EBIT
EUR 9.30 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Mediclin AG is €6.20, about 83.4% above its April 30 closing price of €3.38

The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)